ISRN PharmacologyVolume 2012 (2012), Article ID 104540, 7 pagesdoi:10.5402/2012/104540

Research Article

Activity of Cuban Plants Extracts against Leishmania amazonensis

Marley García,¹ Lianet Monzote,¹ Ramón Scull,² and Pedro Herrera³

¹Department of Parasitology, Institute of Tropical Medicine “Pedro Kourí,” Apdo Postal No. 601, Havana 10400, Cuba²Department of Chemistry, Institute of Pharmacy and Food, University of Havana, Havana 10400, Cuba³Department of Systematic, Institute of Ecology and Systematic, Havana 10400, Cuba

Received 14 November 2011; Accepted 4 January 2012

Academic Editors: S. Tokuyama and T. B. Vree

Copyright © 2012 Marley García et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Natural products have long been providing important drug leads for infectious diseases. Leishmaniasis is a major health problem worldwide that affects millions of people especially in the developing nations. There is no immunoprophylaxis (vaccination) available for Leishmania infections, and conventional treatments are unsatisfactory; therefore, antileishmanial drugs are urgently needed. In this work, 48 alcoholic extracts from 46 Cuban plants were evaluated by an in vitro bioassay against Leishmania amazonensis. Furthermore, their toxicity was assayed against murine macrophage. The three most potent extracts against the amastigote stage of Leishmania amazonensis were from Hura crepitans, Bambusa vulgaris, and Simarouba glauca.

1. Introduction

Leishmaniasis is a protozoan parasitic disease found in 16 developed and 72 developing countries with 12 million cases [1]; it causes around 70000 deaths annually [2]. So far, no vaccine approved for human use is available [3]. Various antileishmanial agents are readily available in the market although none of these chemotherapy drugs are free from harmful side effects and toxicity [4–7]. Currently, the development of new drugs against leishmaniasis is a need.

The interest in plants products, specially in medicinal plants or their extracts, surfaced all over the world due to the belief that many herbal extracts have been extensively used by native populations to treat leishmaniasis [8, 9] and scientific reports have demonstrated their potential [10, 11]. In the present study, the antileishmanial activity of 48 extracts from 46 Cuban plants was tested to validate the antiprotozoal properties of Cuban plants.

2. Methods

2.1. Plant Materials

Vegetative samples of 46 species were used, and their general data are presented in Table 1. All plants were collected and authenticated according to the Cuban Flora by M. S. Ramón Scull and Dr. Pedro Herrera. Their voucher specimens or collector’s numbers were assigned, and a sample was deposited in a herbarium (Table 1).

Table 1: List of plants used in this study and collections data.

Plants species
Family
Part used
Collection date
Geographical areas
Voucher specimen

Allium sativum L.
Alliaceae
Leaves
2006
NBGa, Havana
HAJB-HFCc 87089

Aloe barbadensis L.
Asphodelaceae
Leaves
2010
“La Quiruvina,” Artemisa
HACd 42671

Alternanthera sessilis (L.) R. Br. ex DC.
Amaranthaceae
Leaves
2008
IPFb, Havana
HAJBe 87100

Annona glabra L.
Annonaceae
Leaves
2006
NBG, Havana
HAJB 8300098

Argemone mexicana L.
Papaveraceae
Leaves
2009
IPF
HAJB-HFC 87090

Artemisia absinthium L.
Asteraceae
Leaves
2006
NBG, Havana
HAJB 9700183

Artemisia vulgaris L.
Asteraceae
Leaves
2010
“La Quiruvina,” Artemisa
HAC 42673

Azadirachta indica A.Juss
Meliaceae
Leaves
2008
IPFb, Havana
HAJB-HFC 87099

Bambusa vulgaris Schrad. Ex J. C. Wendl.
Bambusinae
Leaves
2006
NBG, Havana
HAJB 9500087

Bambusa vulgaris Schrad. Ex J. C. Wendl.
Bambusinae
Root
2010
NBG, Havana
HAJB 9500087

Bidens pilosa L.
Asteraceae
Leaves
2006
NBG, Havana
HAJB 9700169

Bursera simaruba (L.) Sarg.
Burseraceae
Leaves
2006
NBG, Havana
HAJB 8603305

Cajanus cajan (L.) Millsp.
Fabaceae
Leaves
2010
“La Quiruvina,” Artemisa
HAJB-HFC 42670

Cassia grandis L.
Leguminosae
Leaves
2006
NBG, Havana
HAJB 8300069

Cecropia peltata L.
Urticaceae
Leaves
2010
NBG, Havana
HAJB 8603239

Chenopodium ambrosioides L.
Chenopodiaceae
Leaves
2010
“La Quiruvina,” Artemisa
ROIGe 4639

Cissus sicyoides L.
Vitaceae
Leaves
2010
NBG, Havana
HAJB-HFC 87092

Citrus limetta Risso
Rutaceae
Leaves
2006
NBG, Havana
HAJB-HFC 87093

Cucurbita maxima Dutch.
Cucurbitaceae
Seeds
2006
NBG, Havana
HAJB-HFC 87091

Cupressus sempervirens L.
Cupressaceae
Leaves
2006
NBG, Havana
HAJB 8603788

Curcuma longa L.
Zingiberaceae
Rhizome
2006
NBG, Havana
HAJB 9700178

Cymbopogon citrate Stapf.
Poaceae
Leaves
2006
NBG, Havana
HAJB 8700008

Hura crepitans L.
Euphorbiaceae
Leaves
2006
NBG, Havana
HAJB 8600198

Indigofera suffruticosa Mill.
Fabaceae
Leaves
2006
NBG, Havana
HAJB 100079

Koanophyllon villosum (Sw.) King & H. Rob.
Asteraceae
Leaves
2010
NBG, Havana
HAJB-HFC 87094

Lepidium virginicum L.
Brassicaceae
Leaves
2006
NBG, Havana
HAJB 8700259

Luffa cylindrica L.
Cucurbitaceae
Leaves
2006
NBG, Havana
HAJB 8600366

Mangifera indica L.
Anacardiaceae
Leaves
2006
NBG, Havana
HAJB 9700183

Melaleuca leucadendron L.
Myrtaceae
Leaves
2006
NBG, Havana
HAJB 8501918

Melia azedarach L.
Meliaceae
Root
2006
NBG, Havana
HAJB 8402273

Momordica charantia L.
Cucurbitaceae
Leaves
2008
NBG, Havana
HAJB 9700180

Ocimum sanctum L.
Lamiaceae
Leaves
2006
NBG, Havana
HAJB 9200485

Parthenium hysterophorus L.
Asteraceae
Leaves
2006
NBG, Havana
HAJB 9700175

Parthenium hysterophorus L.
Asteraceae
Root
2010
NBG, Havana
HAJB 9700176

Petiveria alliaceae L.
Phytolaccaceae
Leaves
2006
NBG, Havana
HAJB 244

Picramnia pentandra Sw.
Simaroubaceae
Leaves
2006
NBG, Havana
HAJB 8303268

Punica granatum L.
Punicaceae
Fruit bark
2006
NBG, Havana
HAJB 8300050

Tradescantia discolor Sw.
Commelinaceae
Leaves
2005
NBG, Havana
HAJB 9200504

Roystonea regia (Kunth) O. F. Cook
Arecaceae
Leaves
2010
NBG, Havana
HFC 87098

Simarouba glauca DC.
Simaroubaceae
Leaves
2006
NBG, Havana
HAJB 8300710

Stachytarpheta jamaicensis (L.) Vahl
Simaroubaceae
Leaves
2006
NBG, Havana
HAJB 9200475

Tabernaemontana citrifolia L.
Boraginaceae
Leaves
2006
NBG, Havana
HAJB 8500720

Tamarindus indica L.
Apocynaceae
Stem bark
2006
NBG, Havana
HAJB 8300068

Thevetia peruviana L.
Caesalpiniaceae
Leaves
2006
NBG, Havana
HAJB-HFC 87095

Trichilia havanensis Jacq.
Meliaceae
Leaves
2010
NBG, Havana
HAJB-HFC 87097

Turnera ulmifolia L.
Turneraceae
Leaves
2009
NBG, Havana
HAJB 8602024

Zerumbet speciosum J. C. Wendl.
Zingiberaceae
Leaves
2010
NBG, Havana
HAJB-HFC 87096

aNBG: the collection of plant was performed in the National Botanic Garden, Havana, Cuba.

bIPF: the collection of plant was performed in the Institute of Pharmacy and Food, Havana, Cuba.

cHFC: Herbarium of National Botanic Garden in the special series of Cuban Flora.

dHAC: Herbarium of Systematic and Ecology Institute.

eHAJB: Herbarium of National Botanic Garden.

fROIG: Herbarium of Experimental Station of Medicinal Plants “Dr. Juan Tomás Roig.”

2.2. Preparation of Plant Extracts

The plant organs were dried in an oven with ventilation system at 30°C and crushed. The fluid extracts were prepared by maceration for seven days using 80% ethanol as solvent and 20% water, according to the Regulation Norm 309 (Regulation Norm, 1992). Solvent was evaporated, and the extracts were lyophilized and dissolved in dimethyl-sulfoxide (DMSO, BDH, England) at 20 mg/mL and stored at 4°C.

2.3. Reference Drug

Pentamidine (Richet, Buenos Aires, Argentina) was used as positive control and a stock solution prepared at a concentration of 10 mg/mL.

2.4. Parasites

The MHOM/77BR/LTB0016 strain of Leishmania amazonensis was kindly provided by the Department of Immunology, Oswaldo Cruz Foundation (FIOCRUZ), Brazil. Parasites were routinely isolated by aspiration with needle from mouse lesions and maintained as promastigotes at 26°C in Schneider’s medium (Sigma-Aldrich, St. Louis, MO, USA) containing 10% heat-inactivated fetal bovine serum (HFBS) (Sigma-Aldrich, St. Louis, MO, USA), 100 g of streptomycin/mL, and 100 U of penicillin/mL, with passage each 3 or 4 days. The parasites were not used after 10 in vitro passages.

2.5. Antipromastigote Screening

Exponentially growing promastigotes (10⁵ promastigotes/mL, 199 L) were plated in 96-well plates. Two microliters of extracts or 2 L of DMSO for control were added to the wells at a final concentration between 6.25 and 100 g/mL. Plates were incubated at 26°C for 72 h. Then, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) solution (15 L) at 5 mg/mL dissolved in saline solution was added to each well. After incubation for additional 4 h, the medium was removed and formazan crystals were dissolved by addition of 100 L of DMSO. Absorbance was determined using an EMS Reader MF Version 2.4-0, at a wavelength of 560 nm and 630 nm as reference [12, 13].

2.6. Cytotoxicity Assay

We determined the IC₅₀ of the extracts on peritoneal macrophage from BALB/c mice. Resident macrophages were collected from peritoneal cavity of healthy BALB/c mice in RPMI 1640 medium (Sigma, St. Louis, Mo, USA) supplemented with antibiotics (penicillin 200 UI, streptomycin 200 g/mL), plated at 10⁶/mL in 96-well Lab-Tek (Costar, USA) and left to adhere for 2 h at 37°C in 5% CO₂. Nonadherent cells were removed by washing with saline solution after 2 h of incubation at 37°C in 5% CO₂. Then, 198 L of medium with 10% of HFBS and antibiotics (penicillin 200 UI, streptomycin 200 g/mL) was added in each well, and later 2 L of extracts dilutions, previously prepared in medium, was added. Macrophages were treated with the extracts from 1.5 to 200 g/mL for 72 h. Cultures with DMSO were included as control treated. The cytotoxicity was determined using the colorimetric assay with MTT as described above in the promastigote assay [13].

2.7. Antiamastigote Activity

Peritoneal macrophages from BALB/c mice were collected, plated at 10⁶/mL in 24-well Lab-Tek (Costar, USA), and incubated 2 h at 37°C in 5% CO₂. Nonadherent cells were removed, and stationary-phase L. amazonensis promastigotes were added at a 4 : 1 parasite/macrophage ratio. Cultures were added for further 4 h, and cell monolayers were washed to remove free parasites. Then, 1990 L of the RPMI complete medium and 10 L of the different extracts were added, following serial dilutions 1 : 2, to obtain final concentrations between 12.5 and 100 g/mL. Plates were incubated for a further 48 h [14]. Cultures as control were included, which were treated with DMSO. Cultures were then fixed with absolute methanol, stained with Giemsa, and examined under light microscopy. The number of intracellular amastigotes was determined by counting the amastigotes resident in 100 macrophages per each sample. Results were expressed as percent of reduction of the infection rate (% IR) in comparison with those obtained with positive controls. The infection rates were obtained by multiplying the percentage of infected macrophages by the number of amastigotes per infected macrophages [15].

2.8. Statistic Analysis

All tests were performed in triplicate, and the median inhibitory concentration (IC₅₀) to parasite and median cytotoxic concentration (CC₅₀) to peritoneal macrophage from BALB/c mice were obtained directly from linear equation of dose-response curves. The results were expressed as their average and standard deviation.

The active extracts that showed an IC₅₀ < 100 g/mL were selected as active against promastigote form, and cytotoxicity was determined. Then, the selectivity index (SI), calculated as ratio of CC₅₀ for macrophage/IC₅₀ for promastigotes, was used to compare the toxicity and activity of the extracts. The extracts with an SI more than 5 were tested against the amastigote form. The extracts with an IC₅₀ ≤ 50 g/mL were considered as active against intracellular amastigotes of Leishmania.

3. Results

The activity of extracts against L. amazonensis promastigotes, the cytoxicity against peritoneal macrophage from BALB/c mice, and the selectivity are shown in Table 2. Between them, 20 extracts showed activity, with an IC₅₀ < 100 g/mL, although only 4 extracts (Bambusa vulgaris, Hura crepitans, Mangifera indica, and Simarouba glauca) demonstrated selective activity against the parasite and were tested against intracellular amastigotes.

Table 2: Antileishmanial activity and cytotoxicity of Cuban plants extracts.

Plants species
I  ± SDb (g/mL)
C  ± SD (g/mL)
SId

A. sativum
153.2 ± 2.1
—
—

A. barbadensis
77.5 ± 0.9
150.3 ± 3.4
2

A. sessilis
>200
—
—

A. glabra
37.8 ± 0.1
—
—

A. mexicana
>200
—
—

A. absinthium
129.0 ± 1.5
—
—

A. vulgaris
55.0 ± 3.2
107.7 ± 5.1
2

A. indica
>200
—
—

B. vulgaris (leaves)
60.5 ± 7.3
276.5 ± 1.2
5

B. vulgaris (root)
191.6 ± 1.1
—
—

B. pilosa
73.7 ± 0.1
222.8 ± 1.1
3

B. simaruba
163.3 ± 1.8

C. cajan
51.7 ± 0.7
132.5 ± 5.7
3

C. grandis
>200
—
—

C. peltata
>200
—
—

C. ambrosioides
>200
—
—

C. sicyoides
>200
—
—

C. limetta
73.6 ± 1.3
210.6 ± 3.9
3

C. maxima
62.2 ± 0.1
161.7 ± 0.9
3

C. sempervirens
>200
—
—

C. longa
>200
—
—

C. citrate
>200
—
—

H. crepitans
16.4 ± 2.1
390.5 ± 8.6
24

I. suffruticosa
75.8 ± 4.5
158.5 ± 6.2
2

K. villosum
>200
—
—

L. virginicum
109.7 ± 1.8
—
—

L. cylindrica
127.9 ± 1.0
—
—

M. indica
51.2 ± 0.1
442.4 ± 2.9
9

M. leucadendron
57.2 ± 2.9
199.2 ± 4.7
3

M. azedarach
168.6 ± 1.9
—
—

M. charantia
59.8 ± 0.4
26.7 ± 0.3
0

O. sanctum
96.9 ± 0.1
216.9 ± 4.8
2

P. hysterophorus (leaves)
54.7 ± 1.2
89.2 ± 1.5
0

P. hysterophorus (root)
46.9 ± 1.7
140.2 ± 0.2
3

P. alliaceae
151.5 ± 4.1
—
—

P. pentandra
140.8 ± 1.4
—
—

P. oleracea
63.9 ± 2.6
125.9 ± 1.9
2

P. granatum
39.4 ± 8.8
129.0 ± 4.6
3

R. spathacea
71.4 ± 1.4
244.6 ± 1.6
3

R. regia
>200
—
—

S. glauca
47.5 ± 0
228.7 ± 8.0
5

S. jamaicensis
111.8 ± 1.2
—
—

T. citrifolia
>200
—
—

T. indica
>200
—
—

T. peruviana
>200
—
—

T. havanensis
>200
—
—

T. ulmifolia
>200
—
—

Z. speciosum
133.1 ± 0.8
—
—

Pentamidine
0.37 ± 0.01
11.7 ± 1.7
32

aIC₅₀: concentration of drug that caused 50% of growth inhibition of promastigotes of L. amazonensis.

bSD: standard deviation.

cCC₅₀: concentration of drug that caused 50% of mortality of peritoneal macrophage from BALB/c.

dSI: selectivity index.

Bold data indicate the extract selected.

Among the four extracts evaluated against L. amazonensis amastigotes, three showed inhibition of growth with IC50 ≤ 50 g/mL. The highest antileishmanial activity was exhibited by H. crepitans, with the lower IC₅₀ value (27.7 ± 0.6 g/mL). The IC₅₀ of B. vulgaris and S. glauca was 41.5 ± 0.6 g/mL and 45.5 ± 0.3 g/mL, respectively. M. indica extract showed an IC₅₀ value of  60.1 ± 3.3 g/mL.

4. Discussion

Natural products are potential sources of new and selective agents for the treatment of important tropical diseases caused by protozoan and other parasites [16]. Only few laboratories are involved in drug evaluation and development against these devastating diseases, particularly against leishmaniasis, which has been considered as a “neglected disease” [17]. In this sense, the potential of plant products as a source of antileishmanial drugs has been demonstrated and considered as a promising approach. Several studies about screening of plants extracts against Leishmania have been reported [18–23].

Different models to evaluate drugs have been used, including promastigote, intracellular amastigote, or axenic amastigote forms of the parasite. The most important method is the counting of intracellular amastigotes, which are the clinical relevant stage of Leishmania in the mammalian host. Conventional procedures involve staining with Giemsa after treatment and manual counting. However, this conventional procedure has limitations such as being time consuming, the use of animals for extraction of macrophages, and the possible error in the counting. Axenic amastigotes forms have been developed to obtain a more simple and reproducible method. These are technically easier and less expensive and require a very shorter time for execution. However, this model lacks information about the behavior of macrophages during the treatment, their possible influence on drug activity, or possible damage received due to toxicity [24]. Alternatively, the promastigote form has been used in screening investigations. Although it is not a clinical relevant stage, it was reported that this parasitic form gives information on specific antileishmanial activity respect to toxicity showed (selectivity of the product). In addition, the tests are easy and highly reproducible [22]. The use of the promastigote form has been widely demonstrated as the preliminary test in screening of plant extract [8, 25, 26].

As part of a screening project of natural plants against protozoan parasites, we tested 48 extracts against Leishmania, which were selected according to the previous literature that mentioned these plants with antiparasitic properties [27]. In addition, the evaluated plants present an easy cultivation and can be obtained in high quantities of samples.

Cuba presents a rich plant population that has been unexploited in the field of antiprotozoals. Nevertheless, previous studies about antileishmanial potentialities of Cuban plants were reported, including Chenopodium ambrosioides [28], Piper auritum [29], and Bidens pilosa [23]. We found that 42% (20 extracts) of the tested products showed leishmanicidal activity with an IC₅₀ ≤ 100 g/mL against promastigotes, of which only 20% (4 extracts) exhibited selectivity (SI > 5) and of them 75% (3 extracts) caused growth inhibition in the antiamastigote assay.

Among the plant species evaluated here, H. crepitans caused the higher inhibition of promastigotes growth (IC₅₀ = 16.4 g/mL) and lower toxicity against host cell (IC₅₀ = 390.5 g/mL), with an SI = 24. This plant showed the highest activity with an IC₅₀ = 27.7 g/mL against the amastigote form. The results demonstrated the presence of compounds with reasonable potency. H. crepitans is a native plant from tropical America that has been used for amoebiasis treatment [30] and against other protozoa such as Plasmodium falciparum [31]. In Nicaragua, this plant is used to treat helmintic diseases as ascariasis [30] and in Loreto, Peru, is used by the population to treat the leishmaniasis [8] with acceptable efficacy. In addition, this extract has shown promising activity against P. falciparum [32], with a low toxicity and a SI > 10. In the literature uses of its seeds are reported as emmenagogue although they can cause toxic effects, including the death of patients [33]. The toxicity of this plant is caused by two toxic albumins (toxalbumins), hurina and crepitina, which are distributed among all plant organs [34, 35].

On the other hand, the leaves extract from B. vulgaris showed an IC₅₀ = 60.49 g/mL against the promastigote form and SI = 5, while the activity was better against the amastigote form, with an IC₅₀ = 41.5 g/mL. However the root extract of this species did not show antileishmanial activity, which would be due to the differential distribution of metabolites in the plant. This finding should indicate that the component(s) responsible for leishmanicidal activity is (are) found in a major percent in the leaves, resulting in the parasite inhibition presented. B. vulgaris is an original tropical plant from Old World that has been cultivated in America [27]. Previously, it has been reported that B. vulgaris leave extract was inactive in a different screening approach because the extract was dissolved in ethanol [23]. This demonstrates the importance of the dissolvent in the screening approaches. DMSO is a membrane permeabiliser and is known for its ability to serve as carried to transport the drugs into cells [36]. Additionally, this extract has shown activity against other protozoa, such as P. falciparum [32]. Other uses include antiparasitic preventive control for dogs [37], cuts, injuries, and swellings [38] and as diuretic in the east population of Cuba [27]. Chemical analysis of B. vulgaris leave extract revealed the presence of different bioactive components, including: alkaloids, tannins, phenolics, glycosides, saponins, flavonoids, and anthraquinones [39] S. glauca also showed a promising antileishmanial activity. The IC₅₀ against promastigotes was similar to that against amastigotes (IC₅₀ of 47.5 and 45.5 g/mL, resp.) and an SI of 5 was obtained. This plant is present in Latin America and has been used for different purposes, for example, in Cuba as emmenagogue, febrifuge, antidysenteric, antihelmintic, and antiherpetic [27], in Haití for the cutaneous lesions [40], and in Guatemala against malaria and amoebiasis [41]. The glaucarrubin is a terpenoids, present in this plant, has been described as responsible for the activity against Gram-positive bacteria and protozoa parasite, specially Entoameba histolytica and P. falciparum [40].

Several reports in the literature have shown the antileishmanial activity of some plant extracts, including the hidroalcoholic extract from C. ambrosioides [42] and Ocimum sanctum [43]. However, we did not observe antileishmanial activity of these plants in this study. This apparent controversial result can be due to the variation of chemical components between plants from different geographic areas, which have been documented [44], including plants from the same country [9].

5. Conclusion

In sum, in this study, 48 Cuban plants extracts were evaluated against L. amazonensis. The extracts of H. crepitans, B. vulgaris, and S. glauca showed promising antileishmanial activity against life cycle stages of the parasite and high selectivity compared with the activity against mouse peritoneal macrophages. For this reason the next step should be the purification and identification of the active principles of these plants.

Acknowledgment

Thanks are due to National Botanic Garden for their cooperation, especially to M. S. Reinier Morejón for helpful advice.

References

F. Chappuis, S. Sundar, A. Hailu et al., “Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?” Nature Reviews Microbiology, vol. 5, no. 11, pp. 873–882, 2007.

J. Guillon, I. Forfar, M. Mamani-Matsuda et al., “Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents,” Bioorganic and Medicinal Chemistry, vol. 15, no. 1, pp. 194–210, 2007.

R. N. Coler and S. G. Reed, “Second-generation vaccines against leishmaniasis,” Trends in Parasitology, vol. 21, no. 5, pp. 244–249, 2005.

L. Kedzierski, A. Sakthianandeswaren, J. M. Curtis, P. C. Andrews, P. C. Junk, and K. Kedzierska, “Leishmaniasis: current treatment and prospects for new drugs and vaccines,” Current Medicinal Chemistry, vol. 16, no. 5, pp. 599–614, 2009.

P. R. Veera, V. Vobalaboina, and N. Ali, “Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres,” Journal of Drug Targeting, vol. 17, no. 2, pp. 140–147, 2009.

H. W. Murray, “Clinical and experimental advances in treatment of visceral leishmaniasis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 8, pp. 2185–2197, 2001.

B. Klllingley, L. E. M. Lamb, and R. N. Davidson, “Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica,” Annals of Tropical Medicine and Parasitology, vol. 103, no. 2, pp. 171–175, 2009.

L. P. Kvist, S. B. Christensen, H. B. Rasmussen, K. Mejia, and A. Gonzalez, “Identification and evaluation of Peruvian plants used to treat malaria and leishmaniasis,” Journal of Ethnopharmacology, vol. 106, no. 3, pp. 390–402, 2006.

M. J. Chan-Bacab, E. Balanza, E. Deharo, V. Muñoz, R. D. García, and L. M. Peña-Rodríguez, “Variation of leishmanicidal activity in four populations of Urechites andrieuxii,” Journal of Ethnopharmacology, vol. 86, no. 2-3, pp. 243–247, 2003.

L. G. Rocha, J. R. G. S. Almeida, R. O. Macêdo, and J. M. Barbosa-Filho, “A review of natural products with antileishmanial activity,” Phytomedicine, vol. 12, no. 6-7, pp. 514–535, 2005.

S. Gupta, B. Raychaudhuri, S. Banerjee, B. Das, S. Mukhopadhaya, and S. C. Datta, “Momordicatin purified from fruits of Momordica charantia is effective to act as a potent antileishmania agent,” Parasitology International, vol. 59, no. 2, pp. 192–197, 2010.

A. Dutta, S. Bandyopadhyay, C. Mandal, and M. Chatterjee, “Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis,” Parasitology International, vol. 54, no. 2, pp. 119–122, 2005.

D. Sladowski, S. J. Steer, R. H. Clothier, and M. Balls, “An improved MTT assay,” Journal of Immunological Methods, vol. 157, no. 1-2, pp. 203–207, 1993.

E. C. Torres-Santos, D. L. Moreira, M. A. C. Kaplan, M. N. Meirelles, and B. Rossi-Bergmann, “Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1234–1241, 1999.

J. C. Delorenzi, M. Attias, C. R. Gattass et al., “Antileishmanial activity of an indole alkaloid from Peschiera australis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 5, pp. 1349–1354, 2001.

C. W. Wright and J. D. Phillipson, “Natural products and the development of selective antiprotozoal drugs,” Phytotherapy Research, vol. 4, no. 4, pp. 127–139, 1990.

P. J. Hotez, M. E. Bottazzi, C. Franco-Paredes, S. K. Ault, and M. R. Periago, “The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination,” PLoS Neglected Tropical Diseases, vol. 2, no. 9, article e300, 2008.

M. S. Gachet, J. S. Lecaro, M. Kaiser et al., “Assessment of anti-protozoal activity of plants traditionally used in Ecuador in the treatment of leishmaniasis,” Journal of Ethnopharmacology, vol. 128, no. 1, pp. 184–197, 2010.

E. Abdel-Sattar, L. Maes, and M. M. Salama, “In vitro activities of plant extracts from Saudi Arabia against malaria, leishmaniasis, sleeping sickness and Chagas disease,” Phytotherapy Research, vol. 24, no. 9, pp. 1322–1328, 2010.

J. El-On, L. Ozer, J. Gopas et al., “Antileishmanial activity in Israeli plants,” Annals of Tropical Medicine and Parasitology, vol. 103, no. 4, pp. 297–306, 2009.

V. Céline, P. Adriana, D. Eric et al., “Medicinal plants from the Yanesha (Peru): evaluation of the leishmanicidal and antimalarial activity of selected extracts,” Journal of Ethnopharmacology, vol. 123, no. 3, pp. 413–422, 2009.

Y. Estevez, D. Castillo, M. T. Pisango et al., “Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group,” Journal of Ethnopharmacology, vol. 114, no. 2, pp. 254–259, 2007.

M. García, L. Monzote, A. M. Montalvo, and R. Scull, “Screening of medicinal plants against Leishmania amazonensis,” Pharmaceutical Biology, vol. 48, no. 9, pp. 1053–1058, 2010.

D. Sereno and J. L. Lemesre, “Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 5, pp. 972–976, 1997.

S. R. Peraza-Sánchez, F. Cen-Pacheco, A. Noh-Chimal et al., “Leishmanicidal evaluation of extracts from native plants of the Yucatan peninsula,” Fitoterapia, vol. 78, no. 4, pp. 315–318, 2007.

A. G. Tempone, P. Sartorelli, D. Teixeira et al., “Brazilian flora extracts as source of novel antileishmanial and antifungal compounds,” Memorias do Instituto Oswaldo Cruz, vol. 103, no. 5, pp. 443–449, 2008.

J. T. Roig, Plantas Medicinales, Aromáticas o Venenosas de Cuba, Editorial Científico-Técnica, La Habana, Cuba, 2 edition, 1974.

L. Monzote, A. M. Montalvo, S. Almanonni, R. Scull, M. Miranda, and J. Abreu, “Activity of the essential oil from Chenopodium ambrosioides grown in Cuba against Leishmania amazonensis,” Chemotherapy, vol. 52, no. 3, pp. 130–136, 2006.

L. Monzote, M. García, A. M. Montalvo, R. Scull, and M. Miranda, “Chemistry, cytotoxicity and antileishmanial activity of the essential oil from Piper auritum,” Memorias do Instituto Oswaldo Cruz, vol. 105, no. 2, pp. 168–173, 2010.

J. A. López-Sáez and J. Pérez-Soto, “Etnobotánica medicinal y parasitosis intestinales en la isla de Ometepe, Nicaragua,” Polibotánica, vol. 30, pp. 137–161, 2010.

V. Muñoz, M. Sauvain, G. Bourdy et al., “A search for natural bioactive compounds in Bolivia through a multidisciplinary approach. Part III. Evaluation of the antimalarial activity of plants used by Altenos Indians,” Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 123–131, 2000.

A. F.-C. Valdés, J. M. Martínez, R. S. Lizama, Y. G. Gaitén, D. A. Rodríguez, and J. A. Payrol, “In vitro antimalarial activity and cytotoxicity of some selected cuban medicinal plants,” Revista do Instituto de Medicina Tropical de Sao Paulo, vol. 52, no. 4, pp. 197–201, 2010.

J. A. Arlington, Cabrits Plants and Their Uses, Ministry of Agriculture, Forestry and Wildlife Division, Roseau, Dominica, 1986.

W. G. Jaffe, “Hurain, a new plant protease from Hura crepitans,” The Journal of Biological Chemistry, vol. 149, pp. 1–7, 1943.

W. G. Jaffé and D. Seidl, “Crepitin, a phytohemagglutinin from Hura crepitans,” Experientia, vol. 25, no. 8, pp. 891–892, 1963.

V. I. Gordeliy, M. A. Kiselev, P. Lesieur, A. V. Pole, and J. Teixeira, “Lipid membrane structure and interactions in dimethyl sulfoxide/water mixtures,” Biophysical Journal, vol. 75, no. 5, pp. 2343–2351, 1998.

C. Lans, T. Harper, K. Georges, and E. Bridgewater, “Medicinal plants used for dogs in Trinidad and Tobago,” Preventive Veterinary Medicine, vol. 45, no. 3-4, pp. 201–220, 2000.

C. Lans, “Comparison of plants used for skin and stomach problems in Trinidad and Tobago with Asian ethnomedicine,” Journal of Ethnobiology and Ethnomedicine, vol. 3, article 3, 2007.

M. T. Yakubu and B. B. Bukoye, “Abortifacient potentials of the aqueous extract of Bambusa vulgaris leaves in pregnant Dutch rabbits,” Contraception, vol. 80, no. 3, pp. 308–313, 2009.

A. Cáceres, Plantas de Uso Medicinal en Guatemala, Colección Monografias, Editorial Universitaria, Guatemala, 1996.

Seminario Tramil 7, Hacia una Farmacopea Caribeña. Investigación Científica y Uso Popular de las Plantas Medicinales en el Caribe, Ediciones Emile Désormeaux, Santo Domingo, Dominican Republic, 1995.

F. J. Patrício, G. C. Costa, P. V. S. Pereira et al., “Efficacy of the intralesional treatment with Chenopodium ambrosioides in the murine infection by Leishmania amazonensis,” Journal of Ethnopharmacology, vol. 115, no. 2, pp. 313–319, 2008.

V. D. Zheljazkov, C. L. Cantrell, B. Tekwani, and S. I. Khan, “Content, composition, and bioactivity of the essential oils of three basil genotypes as a function of harvesting,” Journal of Agricultural and Food Chemistry, vol. 56, no. 2, pp. 380–385, 2008.

N. D. Yuliana, A. Khatib, Y. H. Choi, and R. Verpoorte, “Metabolomics for bioactivity assessment of natural products,” Phytotherapy Research, vol. 25, no. 2, pp. 157–169, 2011.